A feature by Felix Buabeng
Accra, June 24, GNA – Many people probably scrolled past the announcement when it appeared in February.
The Food and Drugs Authority (FDA) had issued a directive requiring certain alcoholic beverages to be withdrawn from the market.
There was no major publicity campaign, no dramatic product recall and no loud public naming of brands.
Just a directive, a deadline and a warning.
The deadline was March 31, 2026.
Some consumers may have assumed the directive would quietly fade away. Some traders appeared to think so too.
It did not.
In late April, the FDA’s Market Surveillance Team, supported by the Ghana Police Service, embarked on enforcement operations across communities in the country.
The exercise led to the seizure of more than 2,100 products, including Bullet Vodka Drink, Vody Vodka Mixed Drink, Cody’s Vodka Energy Drink, Jojo Carbonated Vodka Mix and Bel Ice Vodka Energy Mix Drink, among others.
The action signalled that the regulator was serious about enforcing its directive and protecting public health.
So why were these products targeted?
The concern centres on the combination of alcohol, a depressant, with stimulants such as caffeine, inositol, kola nut, glucuronolactone, ginseng and guarana.
Health experts have long warned that mixing alcohol with stimulants can mask the signs of intoxication. Consumers may feel less impaired than they actually are, leading them to drink more alcohol than their bodies can safely handle.
The result can be dangerous.
A person may appear alert and in control while their judgement, coordination and reaction time are significantly compromised.
This concern is not unique to Ghana.
Several countries took steps years ago to restrict or remove alcoholic beverages containing stimulant ingredients because of the risks associated with their consumption.
Ghana is now taking similar action, and doing so with increasing determination.
The development also raises an important question for consumers.
How often do people examine the ingredients listed on the beverages they purchase?
Many consumers pay attention to a product’s brand, taste or alcohol content, but rarely scrutinise the ingredient list. Yet some stimulant ingredients may not be immediately obvious to the average buyer.
The FDA’s action serves as a reminder that reading product labels is not merely a formality. It is an important step towards making informed choices about what we consume.
The affected products may eventually return to the market in reformulated versions. Some could reappear under different brand names.
That remains to be seen.
What matters now is that consumers become more aware of what goes into the products they buy and consume.
For the moment, the message is simple.
Read the label.
Then decide.
GNA
Edited by Beatrice Asamani Savage